Mizuho Boosts Amgen (NASDAQ:AMGN) Price Target to $208.00

Mizuho Boosts Amgen (NASDAQ:AMGN) Price Target to $208.00

Amgen (NASDAQ:AMGN – Get Rating) had its price target boosted by equities research analysts at Mizuho from $202.00 to $208.00 in a research note issued on Tuesday, The Fly reports. Mizuho’s price objective would suggest a potential downside of 13.06% from the stock’s current price.

A number of other research firms also recently issued reports on AMGN. Piper Sandler upped their target price on shares of Amgen from $255.00 to $260.00 in a research report on Thursday, April 28th. Wells Fargo & Company upped their target price on shares of Amgen from $210.00 to $250.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 9th. Oppenheimer downgraded shares of Amgen to an “outperform” rating and set a $285.00 price target on the stock. in a research report on Tuesday, May 3rd. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 5th. Finally, BMO Capital Markets cut their price target on shares of Amgen from $263.00 to $243.00 in a research report on Thursday, April 28th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $240.40.

Shares of NASDAQ:AMGN opened at $239.24 on Tuesday. The company has a quick ratio of 1.09, a current ratio of 1.44 and a debt-to-equity ratio of 39.31. Amgen has a 12 month low of $198.64 and a 12 month high of $258.81. The firm has a market cap of $127.80 billion, a P/E ratio of 23.55, a P/E/G ratio of 1.65 and a beta of 0.58. The company’s 50-day moving average price is $240.86 and its two-hundred day moving average price is $226.69.

Amgen (NASDAQ:AMGN – Get Rating) last released its earnings results on Wednesday, April 27th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.22 by $0.03. Amgen had a net margin of 21.75% and a return on equity of 165.95%. The company had revenue of $6.24 billion for the quarter, compared to the consensus estimate of $6.09 billion. During the same period in the prior year, the company posted $3.70 EPS. As a group, equities analysts predict that Amgen will post 17.49 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dixon Hughes Goodman Wealth Advisors LLC bought a new position in shares of Amgen during the 4th quarter worth approximately $26,000. Norwood Financial Corp bought a new position in shares of Amgen during the 4th quarter worth approximately $28,000. Landmark Wealth Management LLC bought a new position in shares of Amgen during the 1st quarter worth approximately $28,000. Industrial Alliance Investment Management Inc. bought a new position in shares of Amgen during the 4th quarter worth approximately $31,000. Finally, CKW Financial Group bought a new position in shares of Amgen during the 1st quarter worth approximately $31,000. 79.01% of the stock is owned by institutional investors and hedge funds.

About Amgen (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Share:
error: Content is protected !!